[Evaluation of auditory function in homozygous beta-thalassemia].
We examined the auditory function of 29 subjects affected by homozygous beta-thalassemia, managed with an high transfusion scheme and regularly treated with 40-60 mg/kg/day of desferrioxamine. A group of 29 healthy subjects is studied as control. We found conductive hearing defect in 8 thalassemics (6 bilateral) and sensory-neural hearing loss at high frequencies in 4. Thalassemic patients showed more auditory impairment than controls, an higher incidence of tonsillar hypertrophy, adenotonsillitis and submandibular lymph-node enlargement.
D000158:Acoustic Impedance Tests; D000293:Adolescent; D000328:Adult; D001299:Audiometry; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000009:adverse effects; D005260:Female; D006311:Hearing Disorders / Q000139:chemically induced / Q000175:diagnosis / Q000209:etiology*; D006314:Hearing Loss, Conductive / Q000139:chemically induced / Q000175:diagnosis / Q000209:etiology; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced / Q000175:diagnosis / Q000209:etiology; D006720:Homozygote; D006801:Humans; D008297:Male; D012306:Risk; D013789:Thalassemia / Q000150:complications* / Q000188:drug therapy / Q000235:genetics
D003676:Deferoxamine
Valutazione della funzione uditiva nella beta-talassemia omozigote.